
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women with Severe PPD
Details : LPCN 1154A (Brexanolone) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Depression, Postpartum.
Product Name : LPCN 1154A
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Starts Phase 3 Outpatient Trial of LPCN 1154 for Postpartum Depression
Details : LPCN 1154 (brexanolone) is an oral neurosteroid, a positive allosteric modulator of GABAA receptors. It is being evaluated for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Details : LPCN 1154 (brexanolone) is an oral neurosteroid, a positive allosteric modulator of GABAA receptors. It is being evaluated in phase 2 clinical trials for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | Sage Therapeutics | RTI International | Yale University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brexanolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alcoholism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 30, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | Sage Therapeutics | RTI International | Yale University
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Completes Dosing in Pivotal Study for LPCN 1154 Postpartum Depression Candidate
Details : LPCN 1154 (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator. It is being evaluated for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Details : LPCN 1154 (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator. It is being evaluated for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
Details : LPCN 1154 (brexanolone) is an oral neurosteroid, a positive allosteric modulator of GABAA receptors. It is being evaluated in phase 2 clinical trials for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
Details : LPCN 1154 is targeted to be a differentiated oral option with rapid-onset, robust efficacy, and short treatment duration as a mono or add-on therapy for patients with unresolved depression symptoms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154
Details : LPCN 1154 is an oral formulation of the neuroactive steroid brexanolone for self-administration in development for the treatment of PPD. The active moiety in LPCN 1154 is a bioidentical positive allosteric modulator of y-aminobutyric acid (GABA) receptor...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2023
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brexanolone
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Details : Brexanolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tinnitus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Brexanolone
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All